Lenvatinib - Api
Lenvatinib is a multi-kinase inhibitor that is being investigated for the treatment of various types of cancer by Eisai Co. It inhibits both VEGFR2 and VEGFR3 kinases. The substence was granted orphan drug status for the treatment of various types of thyroid cancer that do not respondtoradioiodine.
Trade name: Lenvima, Lenvanix
Metabolism: CYP3A4, aldehyde oxidase, non-enzymatic
CAS No: 857890-39-2
Molecular Weight: 426.9 g/mol